Essex Investment Management Co. LLC reduced its position in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 51.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,276 shares of the specialty pharmaceutical company’s stock after selling 32,358 shares during the period. Essex Investment Management Co. LLC’s holdings in Paratek Pharmaceuticals were worth $542,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in PRTK. Schwab Charles Investment Management Inc. increased its position in Paratek Pharmaceuticals by 45.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 36,608 shares of the specialty pharmaceutical company’s stock worth $883,000 after purchasing an additional 11,500 shares during the last quarter. Legal & General Group Plc increased its position in Paratek Pharmaceuticals by 13.3% during the second quarter. Legal & General Group Plc now owns 5,865 shares of the specialty pharmaceutical company’s stock worth $144,000 after purchasing an additional 687 shares during the last quarter. Swiss National Bank increased its position in Paratek Pharmaceuticals by 15.8% during the second quarter. Swiss National Bank now owns 30,100 shares of the specialty pharmaceutical company’s stock worth $725,000 after purchasing an additional 4,100 shares during the last quarter. Wells Fargo & Company MN increased its position in Paratek Pharmaceuticals by 9.7% during the second quarter. Wells Fargo & Company MN now owns 17,075 shares of the specialty pharmaceutical company’s stock worth $411,000 after purchasing an additional 1,509 shares during the last quarter. Finally, Alliancebernstein L.P. increased its position in Paratek Pharmaceuticals by 71.3% during the second quarter. Alliancebernstein L.P. now owns 20,900 shares of the specialty pharmaceutical company’s stock worth $504,000 after purchasing an additional 8,700 shares during the last quarter. Hedge funds and other institutional investors own 75.05% of the company’s stock.

Shares of Paratek Pharmaceuticals Inc (PRTK) opened at $12.70 on Friday. Paratek Pharmaceuticals Inc has a 12-month low of $12.63 and a 12-month high of $29.00. The firm has a market cap of $427.59, a PE ratio of -3.40 and a beta of 0.21. The company has a debt-to-equity ratio of 0.49, a quick ratio of 10.53 and a current ratio of 10.53.

Paratek Pharmaceuticals (NASDAQ:PRTK) last announced its quarterly earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.16. Paratek Pharmaceuticals had a negative net margin of 1,236.38% and a negative return on equity of 100.84%. The business had revenue of $0.01 million during the quarter. equities research analysts anticipate that Paratek Pharmaceuticals Inc will post -3.32 EPS for the current year.

In other news, VP Adam Woodrow sold 14,333 shares of the firm’s stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $13.87, for a total value of $198,798.71. Following the completion of the transaction, the vice president now owns 62,367 shares of the company’s stock, valued at $865,030.29. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Douglas W. Pagan sold 16,291 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $14.22, for a total transaction of $231,658.02. Following the completion of the transaction, the chief financial officer now directly owns 39,570 shares of the company’s stock, valued at approximately $562,685.40. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 40,664 shares of company stock valued at $573,226. Company insiders own 4.90% of the company’s stock.

A number of brokerages have weighed in on PRTK. Zacks Investment Research upgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research report on Friday. ValuEngine cut shares of Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Robert W. Baird reiterated a “buy” rating and set a $40.00 price target on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. Guggenheim began coverage on shares of Paratek Pharmaceuticals in a research report on Tuesday, October 24th. They set a “buy” rating and a $44.00 price target for the company. Finally, Cantor Fitzgerald set a $50.00 price target on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, October 17th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $39.25.

TRADEMARK VIOLATION WARNING: “Paratek Pharmaceuticals Inc (PRTK) Position Cut by Essex Investment Management Co. LLC” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/02/09/paratek-pharmaceuticals-inc-prtk-position-cut-by-essex-investment-management-co-llc.html.

About Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.